Prolynx has secured $70 million in a Series A round to propel its targeted protein degrader platform and clinical pipeline. The San Francisco-based biotech is developing a new class of heterobifunctional molecules, called ProTACs, designed to degrade disease-causing proteins with greater tissue selectivity than earlier degrader technologies. Its lead candidate, PLX-101, is a ProTAC targeting a key oncogenic transcription factor and is poised to enter Phase 2 studies in select solid tumors following a completed Phase 1 dose-escalation. The new capital is earmarked specifically for that Phase 2 trial of PLX-101, as well as IND-enabling work for a second, undisclosed ProTAC candidate. While the investor syndicate was not disclosed, the sizable Series A suggests backing from specialist life science VCs familiar with the competitive protein degrader landscape. The financing underscores continued investor appetite for next-generation approaches in targeted protein degradation, a field that has seen significant partnership and IPO activity despite clinical validation hurdles.